Johnson & Johnson (JNJ): Intel Corporation (INTC)’s Gains Lead the Dow’s End-of-the-Week Rise

Page 1 of 2

Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case they’re material to our investing thesis.

Markets are ending the week in a good way today, as stocks have moved higher to end a strong past five days on Wall Street. The Dow Jones Industrial Average has picked up gains of more than 60 points as of 2:15 p.m. EDT, with most of the stocks on the blue-chip index moving higher. Intel Corporation (NASDAQ:INTC) has had a big hand in the Dow’s outperformance, leading the index into the green. Let’s catch up on what you need to know.

Intel Corporation (NASDAQ:INTC)

Intel’s upgrade

Intel Corporation (NASDAQ:INTC) shares are up around 3% after Jefferies upgraded the chipmaker from “hold” to “buy.” An analyst at the company cited Intel’s production of less power-consuming chips, which will help the company expand its reach into mobile and other high-growth areas. Intel has had little success breaking into those new markets so far, with the exception of the server area, where it has established a strong hold.

Still, at least revenue from the company’s server products is growing. Intel Corporation (NASDAQ:INTC) has struggled financially lately, but the company’s data center division — its second-largest by revenue — posted 3.7% sales growth over the first half of 2013. Until Intel can bolster its product portfolio by becoming a real force in the mobile industry, data center sales will need to pick up the slack of slumping PC chip sales, which lost 7% in revenue in that same time frame.

That slump has hit the company’s net margin hard: In the second quarter of this year net margin fell to 15.6% from 20.9% a year ago. The stock has still managed to grow a respectable 13% year to date, but Intel Corporation (NASDAQ:INTC) will have to keep looking for new routes for growth if it wants to please shareholders and justify Jefferies’ upgrade.

Johnson & Johnson (NYSE:JNJ) is not keeping up with its Dow peers today. Shares of the diversified health-care giant are down 0.% to rank among the Dow’s biggest laggards. The company announced today that it will recall one lot of its schizophrenia therapy Risperdal Consta, although J&J was quick to mention that any possible patient risk was low.

Recalls are never a great sign for any health care firm, and Johnson & Johnson (NYSE:JNJ) has had its share of them over the past few years. Nonetheless, for investors, this company has performed admirably and looks on pace to continue its run into the future.

The company’s star immunology blockbuster, Remicade, continues to grow in sales despite already raking in more than $3.2 billion in revenue over the first half of the year. That was a 7.5% gain from the year before, and Remicade has formed a solid cash foundation for J&J to rely on while newer, faster-growing drugs, such as cancer treatment Zytiga, move up the ranks. Zytiga was approved only a few years ago, but the drug is already on pace to hit blockbuster status with more than $1 billion in sales by the end of the year — and Zytiga’s revenue jumped by more than 70% year over year in 2013′s first half.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!